Visão geral da empresa
A clinical-stage biopharmaceutical entity, BioAtla, Inc. focuses on the development of specific and selective antibody-based therapeutics designed for the treatment of solid tumor cancers. The company operates within the Healthcare sector and specifically within the Biotechnology industry, which characterizes its business model as one reliant on high-risk, high-reward research and development phases before potential commercialization. As of the latest available data, the company maintains a market capitalization of $7.49M and employs a workforce of 41 individuals. The annual revenue generated over the trailing twelve months stands at $2.00M. These financial figures indicate that the company operates on a micro-cap scale with minimal revenue generation relative to its market valuation, suggesting that the current market price is driven largely by potential future clinical value rather than current cash flow performance. The combination of a $7.49M market cap and $2.00M in revenue highlights the significant gap between the company's asset valuation and its operational earnings, a common characteristic in early-stage biotechnology firms awaiting regulatory approval or late-stage clinical trial results.
Saúde financeira
BioAtla, Inc. reported a revenue of $2.00M for the trailing twelve months, yet the company recorded a net income of -$59,607,000 and an EBITDA of -$58,332,000. The substantial disparity between the $2.00M in revenue and the nearly $60M in net losses reveals a cost structure dominated by heavy research and development expenditures, administrative overhead, and clinical trial costs that far exceed current sales generation. The free cash flow stands at -$22,801,624, which indicates that the company is burning through cash reserves to fund its operations and development pipeline without generating sufficient operating cash to sustain itself indefinitely. Analysis of the three primary margins shows a Gross Margin of 0.0%, an Operating Margin of -462.8%, and a Profit Margin of 0.0%, all of which reflect the typical financial profile of a pre-revenue biotechnology company struggling with high fixed costs before achieving scale. Regarding liquidity, the company holds $7.12M in cash against $6.20M in total debt, while the debt-to-equity ratio is listed as N/A, suggesting that the capital structure relies heavily on equity financing rather than traditional debt leverage. The current ratio is 0.37, a figure that indicates the company's current assets are less than one-third of its current liabilities, pointing to potential short-term liquidity challenges and a reliance on external financing to meet immediate obligations. Furthermore, the Return on Equity and Return on Assets are listed as N/A and -110.8% respectively, where the negative return on assets reveals that the company's assets are generating negative value on a period basis, likely due to the aggressive spending required to advance its clinical stage product candidates.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is -3.38, a situation that implies earnings are currently negative and the forward metric is likely a calculation artifact or indicates a specific accounting treatment rather than a profitable trajectory. The Price to Book ratio is -7.47, which indicates that the market is valuing the company at a significant premium relative to its book value, or more accurately, that the book value is negative due to accumulated losses and negative retained earnings. Alternative valuation metrics such as the Price to Sales ratio of 3.74 and an EV/EBITDA of -0.11 are utilized to assess the company, where the price-to-sales figure suggests the market is willing to pay a high multiple of current revenue for the potential of its pipeline assets. The stock has traded with a 52-week high of $71.50 and a 52-week low of $4.35, and given the current market capitalization of $7.49M, the valuation sits within a highly volatile range that reflects speculative investor sentiment rather than fundamental earnings power. The Beta is 1.21, which indicates that the stock price is expected to be 21% more volatile than the broader market, a characteristic typical of small-cap biotechnology stocks that react sharply to clinical trial data and regulatory announcements.
Growth & Income
The Revenue Growth Year-over-Year and Earnings Growth Year-over-Year are both listed as N/A, which reflects the lack of historical comparative data necessary to calculate year-over-year growth rates for a company of this size and stage. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue using standard percentage metrics, as the company has not yet achieved consistent profitability or a long enough history of reported financials to establish a growth trend. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that all available earnings and cash reserves are reinvested into growth initiatives such as clinical trials and drug development rather than being distributed to shareholders. The overall growth and income profile for BioAtla, Inc. is characterized by a complete absence of current income generation and undefined historical growth rates, relying entirely on the successful execution of its clinical pipeline to drive future value creation.